AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00804856
Drug: Volasertib
RxNorm normalized name: Volasertib
DrugBank: Volasertib (DB12062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
Trial: NCT00804856
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Trial: NCT01262365
Drug: Epratuzumab
RxNorm normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
Trial: NCT04066088
Drug: Guanfacine extended release (GXR)
RxNorm normalized name: guanfacine Extended Release Oral Tablet
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The starting dose for all subjects will be 1 mg per day. If the medication is well-tolerated, the dose can be raised to 2 mg until day 28 and increased to 3mg for the remaining 4 weeks in the trial. The dose schedule will not be fixed; the treating clinician can delay a planned increase or lower the dose to manage adverse effects. At week 8, the study will be unblinded and subjects will continue treatment for 8 more weeks.
Trial: NCT04940143
Drug: Botulinum toxin type-A (Onabotulinum toxin type-A)
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Botulinum toxin-A (Onabotulinum toxin type-A/Botox®) injection will be administered from three different points, two on the medial head of the gastrocnemius muscle and one point on the lateral head with total 3-6 units/kg dose, under the guidance of electrical stimulation for the detection of the target neuromuscular junction.
Trial: NCT00648375
Drug: Propanolol
RxNorm normalized name: Propanolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will take a 40-mg dose of propranolol immediately after they experience a traumatic memory associated with strong hyperarousal symptoms. Participants may take up to two doses a day, if the doses are separated by at least 6 hours.
Trial: NCT01017393
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01017393
Drug: ketamine free
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02507128
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide were taken 30 min before PCI.
Trial: NCT02439125
Drug: Eltoprazine HCl
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Eltoprazine (DB12883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg b.i.d. orally for 3 weeks
Trial: NCT02439125
Drug: Eltoprazine HCl
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Eltoprazine (DB12883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg b.i.d. orally for 3 weeks
Trial: NCT02439125
Drug: Eltoprazine HCl
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Eltoprazine (DB12883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg b.i.d. orally for 3 weeks
Trial: NCT02207244
Drug: Guselkumab 100 mg
RxNorm normalized name: guselkumab 100 MG/ML
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg by subcutaneous injection at Weeks 0, 4, 12, and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon randomized treatment group and PASI response (Group I). 100 mg by subcutaneous injection at Weeks 16 and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon PASI response (Group II). Starting at Week 28, participants will receive guselkumab 100 mg through Week 72 depending upon PASI response (Group III). All participants will receive guselkumab q8w starting at Week 76 through Week 252.
Trial: NCT00639249
Drug: SA4503 Low
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral administration
Trial: NCT00639249
Drug: SA4503 High
RxNorm normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT00781456
Drug: 91-day Levonorgestrel Oral Contraceptive
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 91-day treatment consisting of 84 blue combination tablets containing 150 µg LNG/30 µg EE and 7 yellow tablets containing 10 µg EE.
Trial: NCT00568646
Drug: MKC-1
RxNorm normalized name: MKC-1
DrugBank: MKC-1 (DB05608)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral MKC-1 capsules, administered twice daily, for 14 consecutive days, in a 28-day cycles
Trial: NCT00705263
Drug: Ribavirin (SCH 18908)
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
Trial: NCT03729284
Drug: Cymbalta Capsules
RxNorm normalized name: Cymbalta
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active Comparator: Cymbalta®- hard gelatinous capsule with delayed release microgranules ( Eli Lilly do Brasil Ltda) equivalent to 60 mg of duloxetine.
Trial: NCT03729284
Drug: Duloxetine Hydrochloride Capsules
RxNorm normalized name: Duloxetine Hydrochloride
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental Drug: Duloxetine hydrochloride - hard gelatinous capsule with delayed release microgranules (Pfizer S.R.L - Argentina.) equivalent to 60 mg of duloxetine.
Trial: NCT02376309
Drug: ND
RxNorm normalized name: SAND
DrugBank: Schisandra chinensis fruit (DB14325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 nandrolone decanoate injection
Trial: NCT00488982
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75mg/m2 every 21 days
Trial: NCT00488982
Drug: Docetaxel and GM-CSF
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75mg/m2 every 21 days and GM-CSF 250mcg/m2 SQ days 15-28
Trial: NCT03801668
Drug: Albumin-bound Paclitaxel plus S-1
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Albumin-bound Paclitaxel 260mg/m2 IV on D1 plus S-1 80mg/m2 PO (Bid) on D1-14 every 21 days.
Trial: NCT03801668
Drug: Oxaliplatin plus S-1
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 130mg/m2 IV on D1 plus S-1 80mg/m2 PO (Bid) on D1-14 every 21 days.
Trial: NCT01148446
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1,4 mg/mq (max 2 mg)IV, day 1
Trial: NCT01148446
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/mq IV, days 1-5
Trial: NCT01148446
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/mq IV/PO, days 1-5
Trial: NCT01148446
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/mq IV, day 1
Trial: NCT01148446
Drug: Vinblastine
RxNorm normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg/mq IV, day 1
Trial: NCT01148446
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/mq IV, day 1
Trial: NCT01148446
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 300 µg tot., SC; days 7-11
Trial: NCT04230174
Drug: 11C-PBR28
RxNorm normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study will evaluate, serially, functional and structural tissue changes in the cortex and WM of subjects with RRMS and progressive disease under Ocrelizumab using 11C-PBR28 MR-PET imaging at baseline and at approximately 12-month follow up.
Trial: NCT03340610
Drug: Alflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal Injection
Trial: NCT00446966
Drug: Omega Three Polyunsaturated fatty acids
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 grams orally twice daily pre-operatively and 2 grams orally daily after until primary endpoint or 14 days.
Trial: NCT00042874
Drug: alvocidib
RxNorm normalized name: Alvocidib
DrugBank: Alvocidib (DB03496)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00042874
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01956591
Drug: Oxybutynin
RxNorm normalized name: Oxybutynin
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients are treated with oxybutynin for hyperhidrosis. Usual maintenance dose is 10mg/day, but dose may vary according to weight, efficacy and side effects. Our standard protocol starts with 2.5mg/day in the first 7 days, progresses to 5mg/day for 14 days and then reaches the usual maintenance dose of 10mg/day afterwards.
Trial: NCT03316963
Drug: Neostigmine Methylsulfate
RxNorm normalized name: Neostigmine Methylsulfate
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After the patient demonstrates snoring and obstruction collapse, the patient will receive the study medication (neostigmine methylsulfate 1mg/mL) into the soft palate with co-administration of intravenous glycopyrrolate 0.2mg. At each of 5 injection sites on the soft palate , 0.5 mL (0.5mg) of neostigmine methylsulfate will be administered, yielding a total of 2.5mg (2.5mL) of neostigmine methylsulfate. The medication will be administered using five 1 mL syringes filled with 0.5 mL neostigmine each. Following administration of neostigmine, the patient will be observed for an additional 4 minutes to examine both vibration and sound emanating from the soft palate. The anticipated time under sedation will be 14 minutes.
Trial: NCT03874052
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03874052
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT00835575
Drug: Mirtazapine 15 mg (Orally Disintegrating) Tablets
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 15 mg, single-dose fasting
Trial: NCT02322593
Drug: TAS-118 plus Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02322593
Drug: S-1 plus Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04476511
Drug: Cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet containing 30.000IU cholecalciferol
Trial: NCT02207244
Drug: Placebo for guselkumab
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo for guselkumab at Week 16, starting at Week 28, participants will continue to receive placebo for guselkumab through Week 72 depending on randomized treatment group and PASI response (Group I), at weeks 0, 4, 12 and starting at week 28 thereafter up to week 72 depending upon PASI response (Group II), at weeks 0, 4, 12, 16, and 20, starting at week 28 through week 72 depending upon PASI response (Group III).
Trial: NCT02207244
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 23.
Trial: NCT02458196
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone: started with prednisone alone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, and maintained at 10mg/d to 12 months.
Trial: NCT02458196
Drug: Prednisone and Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.~Immunosuppressive drugs: Mycophenolate mofetil 1g/d-1.5g/d for 6 months and 0.5/d-1.0g/d for 6 months.
Trial: NCT02207244
Drug: Placebo for adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo for adalimumab \[two 0.8 milliliter (mL) injections\] at week 0 followed by one 0.8 mL injection at weeks 1, 3, 5, and every 2 week (q2w) through Week 23 (Group I and II).
Trial: NCT03884491
Drug: Vortioxetine IV
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: an intravenous (IV) 10 mg dose (1 mg/mL) of vortioxetine infused over 2 hours
Trial: NCT03884491
Drug: Vortioxetine SLA
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-25 mg of sublingual formulation A of vortioxetine
Trial: NCT01659645
Drug: FACBC
RxNorm normalized name: (18F)FACBC
DrugBank: Fluciclovine (18F) (DB13146)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug FACBC will be given intravenously (IV) over 2 minutes prior to performing the PET scan
Trial: NCT00963274
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting dose: 1.3 mg/sq m
Trial: NCT00963274
Drug: Romidepsin
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Starting dose: 8 mg/sq m
Trial: NCT04479566
Drug: Lithium Carbonate 250 MG
RxNorm normalized name: lithium carbonate 250 MG
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients undergoing video assisted thoracic surgery during the morning will take 250mg lithium carbonate 6 hours after surgery.
Trial: NCT04479566
Drug: Calcium Carbonate 500 MG
RxNorm normalized name: calcium carbonate 500 MG
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients undergoing video assisted thoracic surgery during the morning will take calcium carbonate 500mg 6 hours after surgery.
Trial: NCT03884491
Drug: Vortioxetine SLB
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-25 mg of sublingual formulation B of vortioxetine
Trial: NCT03884491
Drug: Vortioxetine SLC
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: formulation SLC: solution of vortioxetine, concentrate (12.5 mg/mL-62,5 mg/mL) 200 uL or 400 uL, SL, 5-25 mg
Trial: NCT00085371
Drug: triapine
RxNorm normalized name: Triapine
DrugBank: Triapine (DB11940)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01070160
Drug: Endometrin (progesterone 100mg vaginal inserts)
RxNorm normalized name: progesterone Vaginal Insert [Endometrin]
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: once a day, 6-8 days as specified (prior to each EMBx)
Trial: NCT01070160
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: per clinical care guidelines
Trial: NCT00563498
Drug: Glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00117468
Drug: DR-2011
RxNorm normalized name: Dr. Numb
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered vaginally from Day 14 to Day 31
Trial: NCT00117468
Drug: Progesterone 8% Vaginal Gel
RxNorm normalized name: progesterone 8% vaginal gel
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered vaginally from Cycle Day 14 to Day 31
Trial: NCT02983682
Drug: Lidocaine Infusion
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive lidocaine infusion of 42 micrograms/kg/minute over tow hours for a total of 5 mg/kg.
Trial: NCT00160459
Drug: Asoprisnil
RxNorm normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg Tablet, oral Daily for 12 weeks
Trial: NCT00160459
Drug: Asoprisnil
RxNorm normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Tablet, oral Daily for 12 weeks
Trial: NCT00160459
Drug: Asoprisnil
RxNorm normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg Tablet, oral Daily for 12 weeks
Trial: NCT02368054
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infiltration anesthesia
Trial: NCT02368054
Drug: Adrenaline
RxNorm normalized name: Adrenaline
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infiltration anesthesia
Trial: NCT02206646
Drug: Metalyse
RxNorm normalized name: Lutalyse
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03107091
Drug: Terlipressin acetate continuous infusion
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose continuous infusion of Terlipressin administered via ambulatory pump over 28 days
Trial: NCT03950362
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administration of Avelumab 10mg/kg Infuse IV over 30-minutes: 1 cycle 5 days before External Beam RadioTherapy, then every 21 days x 8 cycles (6 months)
Trial: NCT00951457
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00951457
Drug: Alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01866007
Drug: Guselkumab (lyophilized formulation)
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive a single SC injection of 100 mg guselkumab prepared from lyophilized formulation.
Trial: NCT01866007
Drug: Guselkumab (liquid formulation with PFS-U)
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with PFS-U.
Trial: NCT01866007
Drug: Guselkumab (liquid formulation with PFS FID)
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with PFS FID.
Trial: NCT01866007
Drug: Guselkumab (liquid formulation)
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive a single IV infusion of 100 mg guselkumab prepared from liquid formulation.
Trial: NCT03330886
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be administered via IV at a 1200-mg dose over 60 minutes every 3 weeks (to be reduced to 30 minutes every 3 weeks if the first dose is tolerated).
Trial: NCT00723970
Drug: Quetiapine Extended Release
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR, 150-300 mg QHS, for 8 weeks
Trial: NCT00429858
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: S-1 is given as follows: 25 mg/m2 bid on days 1-7 and 15-21 of the cycle (28 days)
Trial: NCT00429858
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive gemcitabine at a dose of 1,000 mg/m2 i.v. at a fixed-dose rate (FDR) infusion of 10 mg/m2/minute (100 minutes), once a week for 3 consecutive weeks, followed by one week rest. Each 4 week period is referred to as a treatment cycle
Trial: NCT00653120
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ER capsules, 160 mg, single-dose
Trial: NCT00653120
Drug: Inderal-LA
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ER capsules, 160 mg, single-dose
Trial: NCT03524339
Drug: Tamsulosin
RxNorm normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamsulosin or placebo will be given for 3 days prior to surgery and one week after surgery to determine its effects on postoperative urinary retention.
Trial: NCT00514865
Drug: ONO-2333Ms Experimental 2
RxNorm normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-10 mg QD(once a day) for 8 weeks
Trial: NCT00514865
Drug: ONO-2333Ms Experimental 1
RxNorm normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-2 mg QD(once a day) for 8 weeks
Trial: NCT02096341
Drug: RRx-001
RxNorm normalized name: RRx-001
DrugBank: RRx-001 (DB12060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRx-001 Dose level 1 (16 mg/m2) twice weekly~RRx-001 Dose level 2 (27 mg/m2) twice weekly
Trial: NCT00620893
Drug: Systane
RxNorm normalized name: Systane
DrugBank: Propylene glycol (DB01839)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baseline: Instill one drop in the randomized eye four times daily starting the day after surgery can be used more frequently if needed Month 3: Instill one drop in the randomized eye twice daily